Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 8M | 7M | 6M | 5M |
| Gross Profit | 0 | 640K | -8M | -12M | -10M |
| Operating Income | -5M | -10M | -15M | -19M | -20M |
| EBITDA | -5M | -7M | -15M | -19M | -16M |
| Net Income | -5M | -10M | -14M | -19M | -20M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.46
-2.67% today
1Y Change
-78.87%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pulmatrix, Inc. (PULM) is a Healthcare stock with listed on NASDAQ. The stock last traded around $1.46 and down 78.9% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +46.2%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +46.2%, free cash flow +51.1% with operating margin 0.0% and ROIC -135.7%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PULM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PULM
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PULM Max Drawdown
-83.12%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PULM and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$5.2M
-14.9% YoY
FY Net Income
-$20.2M
-7.1% YoY
Free Cash Flow
-$19.9M
-2.2% YoY
Revenue Growth
-100.0%
EPS Growth
+46.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 8M | 7M | 6M | 5M |
| Gross Profit | 0 | 640K | -8M | -12M | -10M |
| Operating Income | -5M | -10M | -15M | -19M | -20M |
| EBITDA | -5M | -7M | -15M | -19M | -16M |
| Net Income | -5M | -10M | -14M | -19M | -20M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4M | 10M | 19M | 36M | 54M |
| Total Assets | 4M | 10M | 34M | 41M | 59M |
| Total Liabilities | 329K | 996K | 16M | 10M | 11M |
| Shareholder Equity | 4M | 9M | 18M | 31M | 47M |
| Total Debt | 0 | 0 | 9M | 857K | 2M |
| Net Debt | -4M | -10M | -10M | -35M | -52M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
20M
-1.9% YoY
Capital Expenditures
144K
-67.4% YoY
Free Cash Flow
20M
-2.2% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-97.0%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.